<DOC>
	<DOCNO>NCT00356642</DOCNO>
	<brief_summary>The purpose study study investigate safety , tolerability pharmacokinetics GW842470X patient atopic dermatitis . GW842470X inhibitor phosphodiesterase 4 ( PDE4 ) .</brief_summary>
	<brief_title>Study Of Single And Ten Day Repeat Atopical Applications Of GW842470X Cream On The Skin Of Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Inclusion criterion : Atopic dermatitis patient ( moderate severe ) otherwise healthy . BMI range 18.529.9m2 least 2 index lesion BSA involvement &gt; 10 % . 14 day washout current therapy . Exclusion criterion : Patients systemic treatment atopic dermatitis topical transdermal treatment ( nicotine , hormone replacement therapy ) within 14 day prior first application study medication and/or topical treatment tar treatment corticosteroid within 14 day prior first application except 1 % hydrocortisone . Patients must present systemic disorder active skin disease atopic dermatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>PK</keyword>
	<keyword>GW842470X</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>PD</keyword>
	<keyword>Atopic Dermatitis</keyword>
</DOC>